Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology.
Major depressive disorder
Mobile health
Remote measurement technology
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
06 09 2021
06 09 2021
Historique:
received:
20
03
2021
accepted:
17
08
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
10
9
2021
Statut:
epublish
Résumé
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes a clinical illness Covid-19, has had a major impact on mental health globally. Those diagnosed with major depressive disorder (MDD) may be negatively impacted by the global pandemic due to social isolation, feelings of loneliness or lack of access to care. This study seeks to assess the impact of the 1st lockdown - pre-, during and post - in adults with a recent history of MDD across multiple centres. This study is a secondary analysis of an on-going cohort study, RADAR-MDD project, a multi-centre study examining the use of remote measurement technology (RMT) in monitoring MDD. Self-reported questionnaire and passive data streams were analysed from participants who had joined the project prior to 1st December 2019 and had completed Patient Health and Self-esteem Questionnaires during the pandemic (n = 252). We used mixed models for repeated measures to estimate trajectories of depressive symptoms, self-esteem, and sleep duration. In our sample of 252 participants, 48% (n = 121) had clinically relevant depressive symptoms shortly before the pandemic. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem changed between pre-, during- and post-lockdown. However, we found evidence that mean sleep duration (in minutes) decreased significantly between during- and post- lockdown (- 12.16; 95% CI - 18.39 to - 5.92; p < 0.001). We also found that those experiencing clinically relevant depressive symptoms shortly before the pandemic showed a decrease in depressive symptoms, self-esteem and sleep duration between pre- and during- lockdown (interaction p = 0.047, p = 0.045 and p < 0.001, respectively) as compared to those who were not. We identified changes in depressive symptoms and sleep duration over the course of lockdown, some of which varied according to whether participants were experiencing clinically relevant depressive symptoms shortly prior to the pandemic. However, the results of this study suggest that those with MDD do not experience a significant worsening in symptoms during the first months of the Covid - 19 pandemic.
Sections du résumé
BACKGROUND
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes a clinical illness Covid-19, has had a major impact on mental health globally. Those diagnosed with major depressive disorder (MDD) may be negatively impacted by the global pandemic due to social isolation, feelings of loneliness or lack of access to care. This study seeks to assess the impact of the 1st lockdown - pre-, during and post - in adults with a recent history of MDD across multiple centres.
METHODS
This study is a secondary analysis of an on-going cohort study, RADAR-MDD project, a multi-centre study examining the use of remote measurement technology (RMT) in monitoring MDD. Self-reported questionnaire and passive data streams were analysed from participants who had joined the project prior to 1st December 2019 and had completed Patient Health and Self-esteem Questionnaires during the pandemic (n = 252). We used mixed models for repeated measures to estimate trajectories of depressive symptoms, self-esteem, and sleep duration.
RESULTS
In our sample of 252 participants, 48% (n = 121) had clinically relevant depressive symptoms shortly before the pandemic. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem changed between pre-, during- and post-lockdown. However, we found evidence that mean sleep duration (in minutes) decreased significantly between during- and post- lockdown (- 12.16; 95% CI - 18.39 to - 5.92; p < 0.001). We also found that those experiencing clinically relevant depressive symptoms shortly before the pandemic showed a decrease in depressive symptoms, self-esteem and sleep duration between pre- and during- lockdown (interaction p = 0.047, p = 0.045 and p < 0.001, respectively) as compared to those who were not.
CONCLUSIONS
We identified changes in depressive symptoms and sleep duration over the course of lockdown, some of which varied according to whether participants were experiencing clinically relevant depressive symptoms shortly prior to the pandemic. However, the results of this study suggest that those with MDD do not experience a significant worsening in symptoms during the first months of the Covid - 19 pandemic.
Identifiants
pubmed: 34488697
doi: 10.1186/s12888-021-03434-5
pii: 10.1186/s12888-021-03434-5
pmc: PMC8419819
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
435Subventions
Organisme : Alzheimer's Society
ID : 171
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17214
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
Digit Health. 2019 Apr 12;5:2055207619842986
pubmed: 31019722
BMC Psychiatry. 2019 Feb 18;19(1):72
pubmed: 30777041
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
JAMA. 2016 Jan 26;315(4):407-8
pubmed: 26813213
Lancet Psychiatry. 2021 Feb;8(2):121-129
pubmed: 33306975
J Neurol. 2021 Jan;268(1):8-15
pubmed: 32654065
JMIR Mhealth Uhealth. 2019 Aug 01;7(8):e11734
pubmed: 31373275
Int J Clin Health Psychol. 2021 Jan-Apr;21(1):100196
pubmed: 32904715
J Consult Clin Psychol. 2013 Jun;81(3):508-17
pubmed: 23477478
Eval Health Prof. 2010 Mar;33(1):56-80
pubmed: 20164106
Lancet Psychiatry. 2020 Mar;7(3):228-229
pubmed: 32032543
Lancet Psychiatry. 2020 Oct;7(10):883-892
pubmed: 32707037
JMIR Mhealth Uhealth. 2019 Jun 06;7(6):e13384
pubmed: 31172956
J Consult Clin Psychol. 2015 Oct;83(5):964-75
pubmed: 26371618
Brain Behav Immun. 2020 Oct;89:531-542
pubmed: 32485289
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
JAMA Netw Open. 2020 Sep 1;3(9):e2019686
pubmed: 32876685
Front Psychiatry. 2019 Feb 13;10:36
pubmed: 30814958
J Sleep Res. 2020 Aug;29(4):e13074
pubmed: 32410272
J Psychiatr Res. 2020 Jul;126:134-140
pubmed: 31439359
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet Psychiatry. 2020 Aug;7(8):657-659
pubmed: 32531299
Global Health. 2020 Jul 6;16(1):57
pubmed: 32631403
Br J Psychiatry. 2020 Nov 24;:1-10
pubmed: 33228822
Int J Environ Res Public Health. 2021 Mar 10;18(6):
pubmed: 33801836
Lancet Infect Dis. 2020 Sep;20(9):e238-e244
pubmed: 32628905
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852
Br J Psychiatry. 2020 Oct;217(4):540-542
pubmed: 32493516
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
Chronobiol Int. 2020 Aug;37(8):1191-1200
pubmed: 32660352
J Med Internet Res. 2020 Sep 25;22(9):e19992
pubmed: 32877352